Skip to main content
Anuh Pharma Ltd. logo

Anuh Pharma Ltd. — Investor Relations & Filings

Ticker · ANUHPHR ISIN · INE489G01022 LEI · 335800IVKUOYQSJUVH89 BSE.NS Manufacturing
Open in API
Filings indexed 587 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country IN India
Listing BSE.NS ANUHPHR

About Anuh Pharma Ltd.

https://www.anuhpharma.com

Anuh Pharma Ltd. is a manufacturer of Active Pharmaceutical Ingredients (APIs) and bulk drugs, specializing in the production of Macrolides, including Erythromycin salts, Azithromycin, and Clarithromycin. Its product portfolio also encompasses Anti-TB agents such as Pyrazinamide and Ethambutol, Anti-malarials like Chloroquine Phosphate, and a range of Corticosteroids including Dexamethasone and Betamethasone. Operating with global quality standards, the company maintains certifications such as WHO-GMP, EU-GMP, and CEP. Anuh Pharma focuses on large-scale manufacturing and the supply of high-quality intermediates to pharmaceutical formulators worldwide. The organization leverages advanced chemical synthesis capabilities to serve diverse therapeutic segments, ensuring consistent supply chain reliability and regulatory compliance across international markets.

Recent filings

Filing Released Lang Actions
Anuh Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2026 ,inter alia, to consider and approve Audited Financial Results For The ....
Regulatory Filings Classification · 82% confidence The document is a formal notice to the stock exchanges (BSE and NSE) pursuant to SEBI Listing Regulations informing stakeholders of an upcoming Board Meeting to consider financial results, dividends, audit reports, AGM dates, etc. It does not itself contain audited financial statements, final results, or minutes; nor is it announcing a change of directors (it only schedules a meeting where such matters may be considered). It is a regulatory announcement required by the exchanges, fitting the “Regulatory Filings (RNS)” category as a general compliance/regulatory disclosure.
2026-05-15 English
Updates
Regulatory Filings
2026-05-04 English
Approval from World Health Organization (WHO) Prequalification (WHO PQ) for Amodiaquine Hydrochloride USP
Regulatory Filings Classification · 90% confidence The document is a formal regulatory disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, addressed to the stock exchanges informing of a WHO Prequalification approval. It is neither a financial report nor a management discussion nor an earnings release, but a compliance announcement. It fits the ‘Regulatory Filings’ category (RNS).
2026-05-04 English
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details ....
Regulatory Filings
2026-04-30 English
Copy of Newspaper Publication
Regulatory Filings
2026-04-28 English
Newspaper Publication for Second 100 Days Campaign - "Saksham Niveshak."
Regulatory Filings
2026-04-28 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.